|Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations|
DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ...
New England Journal of Medicine 373 (8), 726-736, 2015
|Immune-related adverse events with immune checkpoint blockade: a comprehensive review|
JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ...
European journal of cancer 54, 139-148, 2016
|Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
M Ducreux, AS Cuhna, C Caramella, A Hollebecque, P Burtin, D Goéré, ...
Annals of Oncology 26, v56-v68, 2015
|Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1|
S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ...
Clinical Cancer Research 23 (8), 1920-1928, 2017
|The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids|
A Louvet, S Naveau, M Abdelnour, MJ Ramond, E Diaz, L Fartoux, ...
Hepatology 45 (6), 1348-1354, 2007
|Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease|
P Mathurin, A Hollebecque, L Arnalsteen, D Buob, E Leteurtre, R Caiazzo, ...
Gastroenterology 137 (2), 532-540, 2009
|High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial|
C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ...
Cancer discovery 7 (6), 586-595, 2017
|A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study|
R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ...
The Lancet Oncology 19 (9), 1180-1191, 2018
|Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor|
A Louvet, F Wartel, H Castel, S Dharancy, A Hollebecque, ...
Gastroenterology 137 (2), 541-548, 2009
|Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer|
RB Corcoran, T André, CE Atreya, JHM Schellens, T Yoshino, JC Bendell, ...
Cancer discovery 8 (4), 428-443, 2018
|Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study|
GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ...
The Lancet Oncology 21 (5), 671-684, 2020
|Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2–dependent and other solid tumors|
L Gandhi, R Bahleda, SM Tolaney, EL Kwak, JM Cleary, SS Pandya, ...
Journal of Clinical Oncology 32 (2), 68-75, 2014
|Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE …|
MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ...
JAMA oncology 5 (4), 546-550, 2019
|The evolution of severe steatosis after bariatric surgery is related to insulin resistance|
P Mathurin, F Gonzalez, O Kerdraon, E Leteurtre, L Arnalsteen, ...
Gastroenterology 130 (6), 1617-1624, 2006
|Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment|
R Belkhir, S Le Burel, L Dunogeant, A Marabelle, A Hollebecque, B Besse, ...
Annals of the rheumatic diseases 76 (10), 1747-1750, 2017
|525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028|
YJ Bang, T Doi, F De Braud, S Piha-Paul, A Hollebecque, ARA Razak, ...
European Journal of Cancer 51, S112, 2015
|Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child‐Pugh score|
A Hollebecque, S Cattan, O Romano, G Sergent, A Mourad, A Louvet, ...
Alimentary pharmacology & therapeutics 34 (10), 1193-1201, 2011
|Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).|
DC Cho, JA Sosman, M Sznol, MS Gordon, A Hollebecque, O Hamid, ...
Journal of Clinical Oncology 31 (15_suppl), 4505-4505, 2013
|BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study|
T Kaley, M Touat, V Subbiah, A Hollebecque, J Rodon, AC Lockhart, ...
Journal of Clinical Oncology 36 (35), 3477, 2018
|Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials|
C Ferté, M Fernandez, A Hollebecque, S Koscielny, A Levy, C Massard, ...
Clinical Cancer Research 20 (1), 246-252, 2014